Illicium Verum Extract Inhibits TNF-α- and IFN-γ-induced Expression of Chemokines and Cytokines in Human Keratinocytes
Overview
Affiliations
Ethnopharmacological Relevance: Illicium verum Hook. f. (star anise) has been used in traditional medicine for treatment of skin inflammation, rheumatism, asthma, and bronchitis. This study investigated the anti-inflammatory effects of Illicium verum extract (IVE) in the human keratinocyte HaCaT cell line.
Materials And Methods: We investigated the effectiveness of IVE in tumor necrosis factor-α (TNF-α)/interferon-γ (IFN-γ)-induced human keratinocytes. To measure the effects of IVE on chemokine and pro-inflammatory cytokine expression in HaCaT cells, we used the following methods: cell viability assay, reverse transcription-polymerase chain reaction, enzyme-linked immunosorbent assay, western blotting, and luciferase reporter assay.
Results: IVE inhibited the expression of TNF-α/IFN-γ-induced mRNA and protein expression of thymus and activation-regulated chemokine (TARC/CCL17), macrophage-derived chemokine (MDC/CCL22), interleukin (IL)-6, and IL-1β. Furthermore, IVE decreased TNF-α/IFN-γ-induced mRNA expression of intercellular adhesion molecule-1 (ICAM-1). IVE inhibited nuclear factor (NF)-κB translocation into the nucleus, as well as phosphorylation and degradation of IκBα. IVE inhibited TNF-α/IFN-γ-induced NF-κB and signal transducer and activator of transcription (STAT)1 activation in a dose-dependent manner. In addition, IVE significantly inhibited activation of extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK), and Akt. Furthermore, IVE contained 2.14% trans-anethole and possessed significant anti-inflammatory activities.
Conclusions: IVE exerts anti-inflammatory effects by suppressing the expression of TNF-α/IFN-γ-induced chemokines, pro-inflammatory cytokines, and adhesion molecules via blockade of NF-κB, STAT1, MAPK, and Akt activation, suggesting that IVE may be a useful therapeutic candidate for inflammatory skin diseases, such as atopic dermatitis.
Kim M, Yang Y, Min G, Heo J, Son J, You Y Sci Rep. 2025; 15(1):2371.
PMID: 39827243 PMC: 11742993. DOI: 10.1038/s41598-025-86678-5.
Dadkhah M, Gholizadeh N, Nasimi Doost Azgomi R, Hosseinzadeh S, Hamedeyazdan S, Haghighat K Iran J Pharm Res. 2024; 23(1):e143290.
PMID: 39005731 PMC: 11246645. DOI: 10.5812/ijpr-143290.
Anti-Inflammatory Herbal Extracts and Their Drug Discovery Perspective in Atopic Dermatitis.
Lee J, Kim E, Jeong G Biomol Ther (Seoul). 2023; 32(1):25-37.
PMID: 38148551 PMC: 10762282. DOI: 10.4062/biomolther.2023.102.
Tran T, Wang R, Kim H, Kim Y Front Pharmacol. 2023; 14:1258057.
PMID: 37869754 PMC: 10588637. DOI: 10.3389/fphar.2023.1258057.
Song H, Park S, Kim H, Jang S, Choo B, Kim H Sci Rep. 2023; 13(1):14594.
PMID: 37670127 PMC: 10480230. DOI: 10.1038/s41598-023-41676-3.